Suppr超能文献

T细胞和B细胞流式细胞术交叉配型阳性患者的活体供肾移植

Living-donor kidney transplant in T-cell and B-cell flow cytometry crossmatch-positive patients.

作者信息

Terasaka Soushi, Kitada Hidehisa, Okabe Yasuhiro, Kawanami Sayako, Noguchi Hiroshi, Miyamoto Kyoko, Tsuchimoto Akihiro, Masutani Kousuke, Tanaka Masao

机构信息

Department of Surgery and Oncology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.

出版信息

Exp Clin Transplant. 2014 Jun;12(3):227-32.

Abstract

OBJECTIVES

Complement-dependent cytotoxic crossmatch is an important indicator for kidney transplant. However, there is controversy about treatment for flow cytometry crossmatch-positive cases.

MATERIALS AND METHODS

This was a retrospective study of 127 living-donor kidney transplant recipients from May 2007 to July 2011. We divided patients into 115 flow cytometry crossmatch T-cell and B-cell-negative cases, and 12 T-cell and B-cell-positive cases. Both groups were given 20 mg basiliximab the day of surgery and 4 days after surgery. Common oral immunosuppressive agents used were tacrolimus, mycophenolate mofetil, and methylprednisolone. Flow cytometry crossmatch T-cell and B-cell-negative recipients started immunosuppression 7 days before surgery, T-cell and B-cell-positive recipients started immunosuppression 14 days before surgery. T-cell and B-cell-positive patients also received 200 mg rituximab 1 week before surgery, had 3 plasma exchange sessions before transplant, and received intravenous immunoglobulin 20 g/day during surgery and after surgery for 5 days. We measured flow-panel reactive antibodies of T-cell and B-cell-positive patients just before surgery to check desensitization efficiency. We evaluated patient survival, graft survival, graft function, and frequency of rejection and infectious diseases.

RESULTS

Patient survival and graft survival were 100% in both groups. Flow cytometry crossmatch T-cell and B-cell-positive cases had no rejection events, but T-cell and B-cell-negative groups developed rejection. There was no statistical difference in the incidence of infection and graft function. Flow-panel reactive antibody demonstrated improvement in all T-cell and B-cell-positive cases.

CONCLUSIONS

In living-donor kidney transplant, flow cytometry crossmatch T-cell and B-cell-positive patients are still considered to be at high risk. Although this is a short-term outcome, all T-cell and B-cell-positive patients in this study achieved excellent results with appropriate preoperative and postoperative treatment.

摘要

目的

补体依赖细胞毒交叉配型是肾移植的一项重要指标。然而,对于流式细胞术交叉配型阳性病例的治疗存在争议。

材料与方法

这是一项对2007年5月至2011年7月期间127例活体供肾移植受者的回顾性研究。我们将患者分为115例流式细胞术交叉配型T细胞和B细胞阴性病例,以及12例T细胞和B细胞阳性病例。两组患者均在手术当天及术后4天给予20mg巴利昔单抗。常用的口服免疫抑制剂有他克莫司、霉酚酸酯和甲泼尼龙。流式细胞术交叉配型T细胞和B细胞阴性的受者在手术前7天开始免疫抑制治疗,T细胞和B细胞阳性的受者在手术前14天开始免疫抑制治疗。T细胞和B细胞阳性患者在手术前1周还接受了200mg利妥昔单抗治疗,在移植前进行了3次血浆置换,并在手术期间及术后5天接受了20g/天的静脉注射免疫球蛋白治疗。我们在手术前测量了T细胞和B细胞阳性患者的流式反应抗体,以检查脱敏效果。我们评估了患者生存率、移植物生存率、移植物功能以及排斥反应和感染性疾病的发生率。

结果

两组患者的患者生存率和移植物生存率均为100%。流式细胞术交叉配型T细胞和B细胞阳性病例未发生排斥反应事件,但T细胞和B细胞阴性组发生了排斥反应。感染发生率和移植物功能方面无统计学差异。流式反应抗体在所有T细胞和B细胞阳性病例中均显示出改善。

结论

在活体供肾移植中,流式细胞术交叉配型T细胞和B细胞阳性患者仍被认为处于高风险状态。尽管这是一项短期结果,但本研究中所有T细胞和B细胞阳性患者通过适当的术前和术后治疗均取得了优异的效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验